---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000059"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:25:57.827449+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia

## Summary
- VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.
- First and only aceclidine-based eye drop; once-daily dosing with proven efficacy up to 10 hours.
- Samples and commercial availability expected as early as October 2025; sales activities to begin immediately.
- Approval based on three Phase 3 studies (CLARITY 1,2,3) showing rapid onset within 30 min and consistent near-vision improvement.
- Well-tolerated; most common adverse reactions were instillation site irritation, dim vision, headache, mostly mild and self-resolving.

## SEC filing metadata
- accession: 0001815776-25-000059
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/0001815776-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/lenz-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000059
- JSON: https://secwatch.observer/filing/0001815776-25-000059.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.